Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), today announced that Craig Tooman, previously Chief Financial Officer (“CFO”), has been appointed President, Chief Executive Officer (“CEO”) and Board member of Silence, and Mark Rothera has stepped down as President, CEO and Board member, effective immediately.
February 21, 2022
· 6 min read